Hillsdale Investment Management’s ADMA Biologics ADMA Stock Holding History

Hillsdale Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-322,200	Closed	-$6.39M	–	615
2025 Q1	$6.39M	Sell	322,200 -1,500	-0.5%	-$25.9K	0.33%	44
2024 Q4	$5.55M	Sell	323,700 -13,650	-4%	-$257K	0.28%	66
2024 Q3	$6.74M	Sell	337,350 -229,580	-40%	-$3.57M	0.52%	31
2024 Q2	$6.34M	Sell	566,930 -62,970	-10%	-$528K	0.5%	34
2024 Q1	$4.16M	Buy	629,900 +628,400	+41,893%	+$3.43M	0.33%	114
2023 Q4	$6.78K	Buy	1,500 +100	+7%	+$370	﹤0.01%	477
2023 Q3	$5.01K	Buy	1,400 +420	+43%	+$1.62K	﹤0.01%	515
2023 Q2	$3.62K	Sell	980 -204,720	-100%	-$759K	﹤0.01%	490
2023 Q1	$681K	Buy	+205,700	New	+$711K	0.06%	246

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Hillsdale Investment Management's ADMA Position: Q2 2025 in Review

Hillsdale Investment Management sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 322,200 shares — an estimated $6.39M sold.

Hillsdale Investment Management first reported a position in ADMA in Q1 2023 and held it in 9 quarters. The position peaked at $6.74M in Q3 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

Hillsdale Investment Management reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
Hillsdale Investment Management sold 322,200 ADMA Biologics shares in Q2 2025, an estimated $6.39M.
Hillsdale Investment Management first reported a position in ADMA Biologics in Q1 2023 and held it in 9 quarters.
Hillsdale Investment Management's ADMA Biologics position peaked at $6.74M in Q3 2024.
368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Hillsdale Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.